Gummies Week · UP TO 75% OFF UP TO 75% OFF · Gummies Week Ends in This week only · 76 gummies picks marked down Shop the deals →
Go back
Refer for $20
$20
Refer
Get $20 in Chowcash when you refer friends, stores, and brands to Chow420. Your friends also get $20 towards their first purchase when they accept your invitation.
Login to Refer

Hemp News, Laws & Product Updates

A curated news hub focused on hemp regulation and policy changes, cannabinoids (CBD/Delta-8/Delta-9/hemp-derived THC), lab testing and COAs, product safety, brands, and industry trends.

  • Federal & State Hemp Laws
  • THC Policy
  • CBD / Delta-8
  • Compliance
  • Lab Testing (COA)
  • Product Safety
  • Industry & Brands
Back to Chow420
https://hightimes.com/

Washington Bill Aims To Tackle Cannabis Store Robbery Spree

In a string of robberies, several cannabis retail shops have reported various tactics criminals have been using to get into their businesses in recent months. As these get worse, lawmakers are cranking up the punishments for people involved in such violent crimes. A bill proposal in Washington would tack on an extra year of jail time for people convicted of robbing a cannabis store under certain conditions. Senate Bill 6133 would allow prosecutors in the state to seek a 12-month sentence enhancement if someone convicted of robbing a cannabis store is part of a group, or if a person uses a vehicle to smash into the cannabis store, which is happening very frequently in Washington and other states, particularly on the West Coast. “We need to do something to control the problem,” state Sen. Jim McCune (R-Graham), the bill’s sponsor, said during the committee hearing. If criminals are aware of increased penalties, perhaps that will be enough to dissuade them from participating in the crimes. “I believe that the tougher the penalty, the less the crime,” said McCune. “Protecting the citizens and the pot shop owners and their employees, and overall slow down crime. Now, that’s what the bill is all about.” Under the bill, a “special allegation” with increased penalties can be made if “A cannabis retail outlet, licensed under chapter 69.50 RCW, and the defendant committed the robbery by using a vehicle to damage or gain access to the retail outlet; or A cannabis retail outlet, licensed under chapter 69.50 RCW, and the defendant committed the robbery in concert with another individual or individuals; the court shall make a finding of fact of the special allegation, or if a jury is had, the jury shall, if it finds the defendant guilty, also find a special verdict as to the special allegation.” The proposal received a public hearing on Jan. 29 before the state Senate Law & Justice committee. SB 6133 passed through the Senate Law & Justice Committee on Tuesday and now heads to the Rules Committee before it can be heard by the full Senate. High Times reported on the rise of smash-and-grab robberies taking place in not only Washington, but in Los Angeles and Oakland, California, among other places. Sometimes the criminals opt for a forklift to smash into a cannabis store—basically anything they can get their hands on that can smash through locked doors and barriers. The cash-only status of cannabis businesses inherently makes them a prime target for criminals. Washington in particular has seen an uptick in smash-and-grab style robberies of cannabis stores. In October 2022 a surveillance video from police shows a crew conducting a well-organized armed robbery of a cannabis shop in Tacoma. A car crashed into a Seattle cannabis store in September 2023, for instance, representing another smash-and-grab burglary. The video surveillance from inside the store shows a car ramming into the store full-speed, followed by hooded people running inside and grabbing cannabis and merchandise off the shelves. KING 5 reports that most recently, a stolen KIA was used to crash into a Shoreline cannabis store on Jan. 2. A group of teens and young adults call themselves the “KIA Boyz” because of how often the cars are used in robberies in the area. According to a lawsuit filed against KIA by Seattle City Attorney Ann Davison, the explosion of stealing KIAs and Hyundais started as a TikTok challenge with videos of joyrides. In Seattle from 2021-2022, thefts of KIA vehicles increased by 503%. KING 5 reports that another cannabis store called the Green Lady dispensary in Lynnwood was robbed in the same manner.  “They came through the rear side of the building in February of last year, so February 2023. And then the second hit was through the front, and that was in November of 2023,” Layla Jordan, the executive assistant at Green Lady, told KING 5.  Jordan’s Lynnwood dispensary was targeted twice over the past year, and one of the dispensary chain’s Olympia locations was also hit twice over the past year. Jordan said they have spent hundreds of thousands of dollars dealing with the aftermath of these robberies. “Anytime my phone goes off at 3 a.m., I’m like, ‘Oh no, did we get hit again?'” said Jordan. “In theory, it would help, but the people who are performing these acts, I don’t think they have any regard for the law,” said Jordan. “So, I’m not sure if it’ll make a difference. But it’s still, it’s a nice thought.” Senate Bill 6133 is one approach to convincing criminals that these crimes are simply not worth the risk.

https://hightimes.com/

Cannabeginners: What are Cannabis Alkaloids?

What does cannabis, coca leaf, and all coffee have in common? They all contain alkaloids, a powerful group of medicinal compounds found in plants around the world. While little is presently known about cannabis alkaloids, they are suspected to possess impressive medical benefits like other plant alkaloids.  Alkaloids are “one of the most common groups of chemicals that [have] medicinal properties found in plants,” commonly used alkaloids include “morphine, cocaine, nicotine, caffeine, quinine, ephedrine, and many more.” They derive their name, alkaloid, from the word alkali, chemicals that react like bases, counteracting acids. Usually found in the outer tissues of plants, the bitter flavor of alkaloids is believed to be a natural defense in plants to prevent them being eaten by herbivores, similar to cannabinoids and terpenes which both assist in preventing predation.  While cannabinoids like THC, CBD, CBG, and THCv, are oily, lipohpilic (binds to fats), and hydrophobic (do not bind to water) compounds, alkaloids are a very different class of chemicals. The biggest chemical difference between alkaloids and cannabinoids is that all alkaloids include a nitrogen atom which binds to additional hydrogen atoms. Cannabinoids, on the other hand, do not have any nitrogen atoms and contain a chain of carbon atoms, which gives them their oily character.  Despite their differences, efficient methods to extract both alkaloids and cannabinoids from plants is to simply burn the leaves or other parts that contain the chemicals, or perform a chemical extraction. These methods have been used for thousands of years for both types of chemicals; the caffeine in coffee is chemically extracted by brewing with water, cannabis is smoked, and cocaine was originally extracted through chewing or brewed as a tea.  Cannabis is a very complicated plant and “more than 500 compounds have been reported from C. sativa, of which 125 cannabinoids have been isolated and/or identified as cannabinoids.” Non-cannabinoid constituents of cannabis include “42 phenolics, 34 flavonoids, 120 terpenes and 2 alkaloids.” Though, there is some debate over the number of alkaloids which have been identified. The discovery of alkaloids in cannabis actually manages to predate the discovery of the first cannabinoid, CBN, back in 1896, by more than a decade. In 1881, the first research on the alkaloid cannabinine was presented at the British Pharmaceutical Conference, and two years later another physiologically active alkaloid, tetanocannabin, was discovered. Cannabis alkaloid research then remained dormant until the 1970s. In 1971, a group of scientists isolated four different alkaloids from cannabis, which they named cannabimines A-D. In 1975, two teams of researchers at the University of Mississippi (UMiss) identified and isolated the first spermidine alkaloid, cannabisativine, from the roots, leaves, and stems of both Mexican and Thai cultivars. The next year, the same researchers at UMiss isolated the second spermidine alkaloid, anhydrocannabisativine and showed that cannabisativine could be converted to anhydrocannabisativine.  While the cannabis alkaloids cannabisativine and annhydrocannabisativine were first discovered in Mexican and Thai cultivars, anhydrocannabisativine has since been “found in plant samples of Cannabis from 15 different geographical locations.” Just like how not every part of a cannabis plant has the same amount of cannabinoids, alkaloids are also unequally distributed around the plant. Research has repeatedly shown that, “cannabis roots are not a significant source of cannabinoids or the aforementioned terpenes, but are rich in other compounds, including … alkaloids.” So while terpenes and cannabinoids are concentrated primarily in the trichomes on the leaves, cannabis alkaloids are primarily found in the roots (but can be found in the stems and leaves as well).  While cannabis alkaloids have a lot of medical potential, the specifics of that potential are unknown. In the case of cannabisativine and anhydrocannabisativine, “no pharmacological information is available,” but it is believed that “there are several compounds in cannabis root with potential anti-inflammatory activity, including alkaloids.”  Other researchers have noted that, as a class of compounds, “alkaloids may be used as analgesics, antibiotics, anticancer drugs, antiarrhythmics, asthma medications, antimalarials, anticholinergics, bronchodilators, laxatives, miotics, oxytocics, vasodilators, psychotropics, and stimulants,” and that likely includes cannabis alkaloids. One study of cannabis alkaloids found them to “have diuretic, analgesic, anticancer, antipyretic, and antiemetic effects.” In one study, a petroleum ether solution of cannabis alkaloids and cannabinoids had “a course of action comparable to that of atropine,” a drug commonly given to reduce fluid in the respiratory tract during surgery, which “can also treat insecticide or mushroom poisoning.” It is not clear to what extent those observed effects were due to the alkaloids or the cannabinoids.  Despite being one of the most common groups of medicinal chemicals found in plants, alkaloids are some of the least known chemicals in cannabis. Early research shows that they may have strong medical benefits as part of the entourage of medicinal compounds in cannabis. 

https://hightimes.com/

Drug Maker Recalls ADHD Medicine Over Label Mixup

The U.S. Food and Drug Administration last week announced the voluntary recall of a medicine used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy after the manufacturer of the drug revealed that the wrong pills were found in packages of the medication. The recall covers one lot of the drug Zenzedi, an ADHD and narcolepsy medication manufactured by Massachusetts-based Azurity Pharmaceuticals. In a notice about the recall, the FDA noted that a pharmacist had reported finding pills of an antihistamine, carbinoxamine maleate, in a package of Zenzedi. The voluntary recall was announced by Azurity on January 24 and covers packages of Zenzedi 30 milligram tablets with lot number F230169A and an expiration date of June 2025. The recalled medication was distributed nationwide through retail pharmacies. Pharmacies and drug wholesalers have reportedly pulled the drug from their shelves to comply with the recall. Customers who purchased packages of the recalled lot of Zenzedi are urged to return any remaining pills to the place of purchase. Patients who take the mislabeled medication and have adverse reactions are encouraged to see their doctor.  The two drugs have opposite effects when taken, according to a report from CBS News. Carbinoxamine maleate is an antihistamine that is used to treat allergies and has a sedative effect on some patients, while Zenzedi, a brand name for the drug dextroamphetamine sulfate,  is a stimulant that generally increases a patient’s attentiveness. Zenzedi is used to treat narcolepsy, a sleep disorder that causes overwhelming daytime drowsiness, and ADHD. The FDA added that patients who take carbinoxamine maleate instead of Zenzedi will experience undertreatment of their symptoms. Patients can also have a potentially deadly elevated risk of accidents or injuries and may have drowsiness, increased eye pressure, urinary obstruction and thyroid disorder, among other symptoms, according to the FDA’s recall notice.                                            “Patients who take carbinoxamine instead of Zenzedi® will experience undertreatment of their symptoms, which may result in functional impairment and an increased risk of accidents or injury,” the FDA wrote in a notice about the recall. “Patients who unknowingly consume carbinoxamine could experience adverse events which include, but are not limited to, drowsiness, sleepiness, central nervous system (CNS) depression, increased eye pressure, enlarged prostate urinary obstruction, and thyroid disorder.” Azurity Pharmaceuticals sent recall notification letters to drug wholesalers on January 4 via an overnight letter and has arranged for the return of all affected product at the wholesale level. The company said that no reports of serious injury have been made as a result of the mixup.    The Zenzedi recall comes in the midst of a nationwide shortage of medications used to treat ADHD. The shortage has been affecting supplies of the drug Adderall since a manufacturer experienced production delays in Fall 2022, according to a report from CNN. At least 11 manufacturers of Adderall or generic versions of the drug were listed on the FDA’s shortage list in September 2023. The shortage of ADHD medication has left many patients struggling to fill their prescriptions, according to healthcare professionals.  “A lot of the young people that I’ve been treating have had difficulties getting their medications month to month,” Dr. Warren Ng, a professor of psychiatry at Columbia University Medical Center who also serves as president for the American Academy of Child and Adolescent Psychiatry, told CNN. When taking their prescribed medication, many patients with ADHD are able to function better. But when they run out of their medication, it can have a tremendous impact on their self-esteem. “I’ve seen kids who want to drop out of school, don’t want to continue with their educational path or drop out of college suddenly making the honor roll,” Ng said. And “instead of seeing, being seen as being lazy or dumb or slow, they can envision themselves really utilizing all of their mental, psychological and intellectual abilities to really see themselves for who they are, which is so much more.”

https://hightimes.com/

Connecticut Legal Loophole Allows THC Seltzers at Liquor Stores

Liquor stores in Connecticut—not licensed cannabis retail stores—are selling THC-infused drinks such as seltzers legally, due to a legal loophole regarding dosages listed on the cans. Cannabis retail stores are selling cans listed as one serving, but the same cans of cannabis-infused seltzer, usually running in sizes from 7.5 – 12 ounces, are labeled as five servings in a package at a liquor store or market. All they have to do is ensure that each serving contains less than 1 mg of THC per serving and they can sell the seltzers without violating state law. CT Insider reports that when the drinks are labeled as five servings rather than one, they are technically legal to be sold anywhere in the state, so long as other elements of the packaging are in line with state rules. “You can sell that in a local convenience store. It’s a seltzer. It doesn’t have any alcohol in it. It is a non-alcoholic beverage,” said Larry Cafero, Wine & Spirits Wholesalers of Connecticut executive director, and former Republican leader in Connecticut’s House of Representatives. “The manufacturer, in order to get around a Connecticut law, is creating stickers that turns a 12-ounce can that they had initially labeled as one serving into multiple servings, so that they could comply with the THC-per-serving standard.” “So, we have this little loophole,” he said. State authorities confirmed they are operating within the scope of law. Connecticut’s Department of Consumer Protection (DCP) clarified that the drinks are indeed legal. “A package containing less than 1 milligram of THC per serving and less than 5 milligram per package is not considered cannabis, and may be produced and sold without a license,” DCP spokesperson Kaitlyn Krasselt confirmed.  Connecticut legalized adult-use cannabis in 2021 and later became available for purchase by adults at retail outlets in January 2023. Connecticut Governor Ned Lamont signed legislation to legalize adult-use cannabis in June 2021, ending the prohibition on possession of cannabis by adults 21 and older and creating a framework for regulated adult-use cannabis sales. The bill also included restorative justice and social equity measures, including provisions that led to the expungement of nearly 43,000 marijuana-related convictions.  “This is constantly evolving, and we realized as a committee that we’ve got to get further ahead of this so that’s why this session we’re going to be changing that definition to make it even just a more bright line rule,” said state Rep. Michael D’Agostino (D-Hamden), who is also chairman of the legislature’s general law committee.  The current plan is to drop the THC limit to .5 mg per container, D’Agostino said. Any products containing more THC than that would only be available in licensed cannabis retail outlets. “The question is, what is cannabis or not cannabis right now? The products that do not meet the definition, i.e. under 5 milligrams of THC per container, are not cannabis and therefore they’re not subject to the cannabis laws,” D’Agostino said. “But once we change this and lower the threshold, even more of those laws will apply.” DCP issued further guidance recently to liquor stores in the state, clarifying that while THC-infused seltzers are legal to sell, they cannot be labeled as “cannabis.” That includes seltzers labeled as “canna-beverage.” As a result, some liquor stores began removing products from their shelves after receiving the guidance.  The legislative session convenes Feb. 7. Cannabis consumers in the state are now able to purchase larger amounts per transaction. Connecticut’s cannabis regulatory agency announced in November 2023 that it is increasing the amount of cannabis that can be bought in a single transaction by doubling the state’s limit on recreational marijuana purchases. Under the new regulations approved by the Connecticut DCP, adult-use cannabis consumers will be permitted to purchase up to a half-ounce, or about 14 grams, of cannabis flower or its equivalent beginning in December 2023.  Medical cannabis in the state is another story. The limit on purchases of medical cannabis has not been changed. It remains at 5 ounces of cannabis flower or the equivalent monthly, with no limits on purchases in a single transaction. “DCP has continually reviewed available supply and demand since prior to the launch of the adult-use cannabis industry in January 2023,” DCP Commissioner Bryan T. Cafferelli said in a statement. “As more retailers, production companies and other supply chain licensees have come online, the capacity of the industry has increased. We are confident this measured approach to adult-use sales has resulted in a healthy market for businesses, and a safe and fair marketplace for adult-use cannabis consumers and medical marijuana patients.” Details are being ironed out regarding where cannabis seltzers can be sold in the state.

https://hightimes.com/

DEA Re-Hires Agent Who Was Fired for Taking CBD

The Department of Justice has rescinded a DEA decision to fire a special agent who was let go due to a positive reading for CBD on a drug test. DEA special agent Anthony L. Armour will be re-hired as a special agent and be reimbursed for back pay and legal expenses after a years-long court battle that stretches back to 2019 when a routine drug test showed he had been using CBD, which Armour maintained in court was for the purpose of treating chronic pain in lieu of highly-addictive opioid based painkillers. “I’m excited to be getting back to work at DEA,” Armour said to The New York Times. “I hope to finish my career at DEA by helping its mission in taking dangerous drugs like fentanyl off the streets.” Armour’s battle with chronic pain goes back to an injury he sustained during his college football career. He was also injured on the job as a DEA agent in a car crash during a surveillance operation, after which he suffered from back pain and a sprained neck. He ordered CBD products and a vaporizer from the internet, under the impression that he was not taking any illegal risks as the 2018 Farm Bill federally legalized hemp products.  “For Armour and many others in this country, this change meant new opportunities—particularly as to CBD, a non-THC cannabinoid in the cannabis plant,” a portion of the lawsuit said. “Armour hoped CBD oils could play a role in his pain management. That he did is unsurprising. From Martha Stewart to Wrigley Field, CBD has become embedded in American culture.” After he failed the drug test, Agent Armour turned the CBD products he had ordered into his superiors. Under federal law, hemp-derived products are defined as such if they contain less than 0.3% THC (please follow these handy-dandy little hyperlinks if you want more information on the clusterfuck of loopholes the Farm Bill created with regard to hemp-derived cannabis products). Of the three different hemp-based products Agent Armour turned in, court documents showed that two of them tested within the 0.3% THC range but one of them tested above the allowed threshold at 0.35%, which could be due to the notoriously unreliable potencies of hemp products and the methods by which they are tested. The DEA even went so far as to double down on their decision years into the lawsuit in late August of 2023. They filed a court brief defending Agent Armour’s termination just days before the Department of Health and Human Services officially recommended the federal rescheduling of cannabis from Schedule 1 to Schedule 3. The DEA also issued an official notice to all DEA employees after Armour’s termination to avoid all CBD products despite their federally legal status. “Mr. Armour was an outstanding DEA agent when he took a chance in 2019. He believed it was unlikely that CBD products would cause him to test positive for marijuana, but he knew it was possible, and he bought those unregulated products on the internet and consumed them anyway,” the DEA brief said. “Mr. Armour argues that he ‘displayed negligence or poor decision-making,’ and DEA properly held him accountable for his poor decisions when they resulted in a verified positive drug test. DEA lost trust in Mr. Armour and properly removed him.” Despite a years-long fight to keep Agent Armour off the payroll the DEA has agreed to reinstate him and pay him $470,000 in back pay and legal fees, according to the New York Times who obtained a copy of the court filings from earlier this month. Agent Armour told the New York Times he still sees value in using CBD for pain management but that he will consult a medical professional for viable alternatives upon his return to work.  “Federal drug testing policies—and importantly, attitudes about drug testing—have not caught up with the times. I’m not the only career law enforcement officer in this country with chronic pain, nor am I the only law enforcement officer that has turned to legal cannabis products to address pain,” Agent Armour said in court testimony in September. “Nobody should have to choose between suffering pain and serving our country.”

https://hightimes.com/

‘Peaky Blinders’ Paul Anderson Slapped with Fine in Drug Possession Case

Arthur Shelby is a troubled soul. The Peaky Blinders character must live under his younger brother, Thomas Shelby’s shadow, and deal with often hard-to-watch, but somehow, relatable, acts of violence, towards both others and himself, self-medicated with drugs and Jesus. And based on recent headlines (in the real world), it appears that, at least for some of such, the actor who plays Arthur, Paul Anderson, opts for Method acting, which aims to foster genuine portrayals by immersing oneself in and embodying the internal motivations and emotions of a character. So, basically, acting like the character off screen as well as when the cameras are rolling.  As The Guardian reports, Anderson has been fined for possession of drugs. These include crack cocaine, amphetamines, in addition to prescription substances, diazepam (Valium) and pregabalin. The incident occurred on Boxing Day, the party-fueled British holiday that is held the day after Christmas. His lawyer claims that the actor uses the drugs to break into character to please fans who recognize him.  Where did Anderson land himself into trouble? At his local pub, of course, who contacted the coppers after the bar’s manager noticed “crack cocaine fumes coming from the disabled toilet after the actor walked out,” MailOnline reports. He was with a friend and his baby.  On Thursday, the 48-year-old actor stood before Highbury Corner magistrates court, facing charges of possessing class A crack cocaine, class B amphetamines, and two types of class C prescription drugs. He admitted to all four counts, resulting in a total fine of £1,345. Reports indicate that Anderson only spoke to acknowledge his pleas and to verify his identity and north-west London address. Anderson’s attorney, addressing the court in mitigation, reportedly stated: “You will recognise the defendant from a very intense part that he has played in a recent television programme. He is often recognised and does his best to please fans of the show by slipping into character. “He was recognised that Boxing Day and tried to play up for these people. And because of the lifestyle he leads people often give him inducements.” The lawyer further noted that Anderson had not been using crack cocaine, but conceded: “He has found himself in an unfortunate position and should have had the strength to say no.” While this news is hard not to pass on for all the Peaky Blinders fans, there’s a lot to unpack that’s not so funny. First, turning to the U.S., if you want to get angry, remember that while cannabis remains a Schedule I substance, cocaine (even though the sentencing guidelines have historically been much harsher, as the result of laws that tend to lock up more poor than rich folks), is only a Schedule II. And, while we don’t know the exact details of how and when Anderson was using, any stimulant as strong as crack, for the sake of one’s health, should not be paired with amphetamines.  Diazepam, the brand name of Valium, is a benzodiazepine. It’s in the same anti-anxiety drug class as pills such as Xanax, Klonopin, and Ativan. When benzodiazepines hit the market in the 1960s, chemists thought they’d cured anxiety. However, as is becoming increasingly reported, unlike cannabis for anxiety, such medications are just too easy to develop a physical dependence on when used other than prescribed, which is as-needed, or on a short-term basis.  While, if you want to take a tolerance break from cannabis, while you might miss it, one can just put down the herb and not think too much about it, with benzos, suddenly stopping them after continued use is no joke, like, comes with risks of seizures if not done correctly. As detailed in the Ashton Manuel, the bible for getting off of benzos, if one is weaning off something like Xanax or Klonopin, it’s actually recommended to switch to Valium and then slowly taper off as it’s less potent and has a longer half-life. As High Times reported, Sub-anesthetic ketamine infusions, which are already used for treatment-resistant depression (TRD), may also help people through benzodiazepine withdrawal, new research published in Neuropsychopharmacology shows. However, of the substances found, MailOnline reports that Anderson later tested positive for opiates and cocaine (not crack cocaine), the court heard, so while there’s possession charges, we have no idea of the actor’s personal use or medication schedule. But we’re on your side, Arthur Shelby. 

https://hightimes.com/

Cannabis Ballot Initiative Title Rejected by Arkansas Attorney General

Arkansas Attorney General Tim Griffin recently rejected a medical cannabis ballot measure because of its title. The Arkansas Medical Cannabis Amendment of 2024 was submitted on Jan. 12 by Stephen Lancaster of the law firm Wright Lindsey & Jennings LLP. Griffin responded to the submission, although the opinion was initially prepared by Assistant Attorney General William R. Olson on Jan. 29, explaining the reasoning behind his decision to reject the measure in its current form. He clearly states in the beginning of this letter that his decision is not a reflection of his support or opposition to this ballot measure, or any others. “My decision to certify or reject a popular name and ballot title is unrelated to my view of the proposed measure’s merits,” Griffin began. “I am not authorized to consider the measure’s merits when considering certification.” However, ballot titles are required to be written in a very specific way. Those who write the measures must ensure that the titles contain all of the essential facts “which would give the voter serious ground for reflection,” but also attempt to keep it brief. “The ballot title is not required to be perfect, nor is it reasonable to expect the title to address every possible legal argument the proposed measure might evoke,” Griffin explained. “The title, however, must be free from any misleading tendency—whether by amplification, omission, or fallacy—and it must not be tinged with partisan coloring. The ballot title must be honest and impartial, and it must convey an intelligible idea of the scope and significance of a proposed change in the law.” Griffin continued to share the core reason behind the rejection, explaining that the title was not formatted properly and contained ambiguous statements. “Where the effects of a proposed measure on current law are unclear or ambiguous, I am unable to ensure the popular name and ballot title accurately reflect the proposal’s contents until the sponsor clarifies or removes the ambiguities in the proposal itself.” Griffin is sending the ballot measure authors back to the drawing board to fix the wording. The header, for instance, currently reads “Be it Enacted by the People of the State of Arkansas,” but wording including “enacting clauses” is only required for bills, not constitutional amendments, which may cause voters to be unsure if this is a bill or a constitutional amendment. He also suggested new text to a section that discusses advertising, and ambiguous wording for “rules shall also require child-proof packaging,” addresses that “medical cannabis” as a phrase is not defined anywhere, noting that the interchangeable use of “marijuana plants” and “cannabis plants” be just “cannabis plants” to avoid confusion, and more. If the Arkansas Medical Cannabis Amendment of 2024 is passed, it would amend the constitution to allow patients and caregivers to cultivate up to seven mature cannabis plants, as well as seven younger plants, expand the qualifying conditions of medical cannabis to include more than the current 18 conditions, allow out-of-state patients holding medical cannabis cards to purchase cannabis in Arkansas, remove fees for cannabis card applications, and allow those cards to last for three years instead of one. It also includes a section entitled “Effect of future federal classification of marijuana” which would permit possession of up to one ounce of cannabis if the federal government decides to remove cannabis from the list of controlled substances. The Arkansas Advocate published an article on this topic and noted that the advocate group can only begin collecting signatures once Griffin has signed off on a ballot measure. After that, they have until July 5 to submit 90,704 signatures in order to qualify for the ballot in November. Erika Gee, an attorney representing Arkansans for Patient Access, shared a statement with the news outlet regarding what’s next. “Arkansans for Patient Access is reviewing Attorney General Tim Griffin’s ballot proposal opinion. We intend to address the issues raised and resubmit,” Gee said. “We are confident ballot language will be presented that ultimately gains approval.” Arkansas voters legalized medical cannabis in November 2016 through Amendment 98, and sales began in May 2019. In August 2022, a recreational cannabis ballot initiative from Responsible Growth Arkansas was rejected because of its name and title. The group quickly filed a lawsuit  “to challenge the State Board of Election Commissioners’ thwarting of the will of the people and their right to adopt laws by initiative.” The Arkansas Supreme Court said that the measure would still appear on the ballot, as Arkansa Issue 4. However, in November 2022, 56.25% of voters voted no, while only 43.75% voted yes. Late last year, the Arkansas Medical Marijuana Commission announced that medical cannabis taxes were helping to fund kids’ school lunches in the state. The commission stated that while the state collected $115 million from cannabis taxes, an estimated $87 million was granted for food insecurity.

https://hightimes.com/

Alaska Lawmaker Introduces Psychedelics Task Force Bill

An Alaska lawmaker has introduced a bill to create a task force to study the potential medical uses of psychedelic drugs including psilocybin and MDMA. The legislation, Senate Bill 166, was introduced earlier this month by Democratic state Senator Forrest Dunbar. If passed by the legislature and signed into law by Republican Governor Mike Dunleavy, Dunbar’s bill would establish a task force that would be given one year to study how psychedelics might be used to address Alaska’s mental health challenges. The task force would investigate paths to legalize psychedelics, requirements for licensing and insurance, and barriers to access to the drugs. “We want Alaska to have a regulatory framework to potentially allow medical providers to use the substances, which had been shown in sort of the early data of the tests to potentially have really positive impacts on people dealing with trauma and with addiction,” Dunbar said in a statement, according to a report from Alaska Public Media.  The psychedelics task force created by the legislation would consist of people representing the healthcare needs of Alaska Natives, military veterans and survivors of domestic abuse and sexual assault. Dunbar said it is important to include Alaska Natives in the task force, noting that other states have not included representation of Indigenous communities and traditional healers in their discussions about psychedelics policy reform. Dunbar introduced Senate Bill 166 in anticipation of a potential change in the legal status of psychedelic drugs at the federal level. Clinical research and other studies into psychedelics such as psilocybin and MDMA have shown that the drugs have potential therapeutic benefits, particularly for serious mental health conditions such as depression, PTSD, substance misuse disorders and anxiety.  “It doesn’t work for everyone, but there are certainly people who could access these substances and potentially have life changing medical results,” Dunbar said. Research published in the peer-reviewed journal JAMA Psychiatry in 2020 found that psilocybin-assisted psychotherapy was an effective and quick-acting treatment for a group of 24 participants with major depressive disorder. A separate study published in 2016 determined that psilocybin treatment produced substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. In 2017, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for psychotherapy utilizing MDMA, the psychedelic drug commonly known as Ecstasy, indicating that the therapy is a significant improvement over existing treatments. Last month, MAPS Public Benefit Corporation (MAPS PBC), a subsidiary of the groundbreaking psychedelics nonprofit advocacy group the Multidisciplinary Association for Psychedelic Studies (MAPS), announced it had submitted an application seeking FDA approval for MDMA-assisted therapy. Only weeks later, the organization announced it had changed its name to Lykos Therapeutics and had raised $100 million in financing to develop psychedelic therapies. As the research continues, Dunbar said it is important to address psychedelics policy including current prohibition and potential legalization so the drugs will be available to people who can benefit from them. “The hope is because these are medical treatments that we would find a way to bill insurance like anything else,” Dunbar said. “How do we make sure we can bill Medicaid and bill private insurance? And I know the indigenous community in particular needs to think about, and will help guide the task force, so that we can make sure we’re getting funds into the traditional healers’ hands as well.” Melissa Bradley, an epidemiologist based in Anchorage who studies psychedelic medicines, said that she became interested in the field after seeing the strong research data. She notes that psychedelic therapy is not an easy undertaking. Many patients find the experience challenging or upsetting during treatment, but long-lasting improvements in mental health have been reported for many patients.  Most research into the therapeutic potential of psychedelics is conducted in a controlled environment. Although the method is effective, finding ways to use the drugs in other, less controlled settings could be the key to greatly expanding access to psychedelic therapy.  “To really figure out the mystery of psychedelics is figuring out the mysteries of consciousness,” Bradley said. “And, we’re kind of poking at that, on the research side of things, but it’s also moving forward, in terms of policy. And so, it will be kind of a Wild West in terms of policy and regulations.” Dunbar’s bill has been referred to the Senate Labor and Commerce Committee for consideration. Democratic State Representative Jennifer Armstrong has filed companion legislation to Senate Bill 166 in the Alaska House of Representatives, where the measure has been assigned to the Health and Social Services Committee. No hearings have yet been planned for the bills, but Dunbar said he hopes to have one scheduled for early February.

https://hightimes.com/

Psilocybin Treatment Bill Proposed in Hawaii

A new bill was introduced in Hawaii last week on Jan. 24, which aims to establish a regulatory framework for therapeutic psilocybin if passed. However, in its current form, the bill would help protect patients who choose that form of medicine, rather than fully legalize psilocybin. Senate Bill 3019 was introduced by Sen. Chris Lee on Jan. 24, and a companion bill, House Bill 2630, was introduced on Jan. 23 by 14 representatives. “…the purpose of this Act is to ensure that people who struggle with trauma and treatment-resistant mental health ailments are not penalized by the State for the use of psilocybin for therapeutic purposes when the patient’s licensed mental health professional provides a professional recommendation that the benefits of therapeutic use of psilocybin would likely outweigh the health risks for the qualifying patient,” the bill stated. Additionally, should any psilocybin products or paraphernalia be seized by law enforcement and a defendant proves in court that they consume legally through the program, law enforcement would be forced to return the products. However, if any patient attempts to claim they use psilocybin for therapeutic purposes to avoid arrest, they will be charged $500. According to SB 319, the benefits of the bill would be limited to those who have a high school diploma or equivalent degree, are currently 21 years or older, must be a resident in Hawaii, and would have to undergo a “psychedelic integration training program” that has been approved by the Office of Wellness and Resilience (OWR). Once a person qualifies, they could potentially gain access to psilocybin treatment if they suffer from any of the following conditions: “post-traumatic stress disorder (PTSD), treatment-resistant depression or major depressive disorder, end-of-life anxiety, existential stress, and demoralization, anorexia, bulimia, and other eating disorders, addiction, obsessive compulsive disorder.” Additionally, other mental health conditions could also qualify for psilocybin if it’s approved by the Department of Health and requested by a licensed mental health professional. Therapy sessions would be structured in three phases. First, the preparation session, which would allow the patient to meet with a facilitator. Second, the administration session, where the patient “purchases, consumes, and experiences the effects of psilocybin” while the facilitator supervises. Finally, an integration session would be held, which would allow the facilitator to offer care for the patient and inform them about peer support and other resources that could be beneficial to them. The OWR announced in August that the Breakthrough Therapies Task Force held its first meeting on Aug. 29, 2023. Its role is to prepare how to implement therapeutic programs that include MDMA and psilocybin. Lee is one of the members, in addition to 10 others, who are members of the task force. Hawaiian legislators’ approach to psilocybin treatment is much different than the way similar laws have been crafted in states such as Oregon and Colorado. The first psilocybin treatment center to be licensed and to begin operating in Oregon, EPIC Healing Eugene, had thousands of people waitlisted just three months after it opened in June 2023. An end of year report stated that by the end of 2023, more than 700 people had experienced psilocybin at treatment centers across the state. Colorado’s psychedelics bill was passed by voters in 2022 and signed by Gov. Jared Polis in May 2023. It removed criminal penalties for possession and consumption of substances such as psilocybin, ibogaine, mescaline, and DMT. These substances can also be shared (ibogaine is the only exception), but not sold, and it permits the home cultivation of mushrooms within a 12 x 12 foot space. In November 2023, Hawaii Attorney General Anne Lopez announced a 294-page plan to legalize adult-use cannabis. The proposal included a 4.25% excise tax on adult-use products, plus a 10% tax on surcharge. It also included a way for illegal cultivators to enter the legal industry by providing grants through a social equity program. “The most important thing we can do is we can bring the people who have been growing and selling marijuana illegally into the legal market,” Lopez said. Medical cannabis dispensaries that have already gone through the hurdles of licensing would be among the first to sell in a recreational market. “They’re already standing up, they’re already growing, they are already prepared to go to market,” Lopez explained. Some legislators expressed their approval of Lopez’s proposal late last year, including House Judiciary Chair David Tarnas. “The attorney general has done a really good job pulling together all of the different input and providing a comprehensive bill,” Tarnas said. Sen. Jarrett Keohokalole called it “the best version to date. And part of it is the efforts to try and address a lot of the issues that came up along the way.”

https://hightimes.com/

Leaders, International Authorities Unite After Historic Fiji Drug Bust

Police seized nearly five tons of methamphetamine in Fiji, equivalent to more than $2 billion in Fijian dollars (approximately $886.2 million USD). The first Jan. 14 raid resulted in seizure of more than three tons of meth at a warehouse on the western side of Fiji’s main island near the country’s main international airport, according to an OCCRP report. The second raid took place Jan. 20, with Fiji’s public prosecutor sanctioning charges against 13 people in connection to the raids, RNZ reports. Those accused have been charged with unlawful possession of illicit drugs, according to a statement from the Office of the Director of Public Prosecutions (ODPP). “Of the 13 accused persons, two are also charged with unlawful importation of illicit drugs. It is alleged that the accused persons without lawful authority, facilitated the importation and were found in possession of 4.8 tonnes of methamphetamines, an illicit drug, the statement says. The ODPP also said that three of the 13 suspects were also charged with possession of property suspected of being proceeds of crime. “It is alleged that the three accused persons were found in possession of cash (local and overseas currency) suspected of being proceeds of crime,” the statement said. One of the 13, Justin Ho, was previously charged for exporting 2015.7 grams of cocaine from Sydney in 2018 while working as a flight attendant for Fiji Airways. Ho, and the other suspect, ended up walking free after the drugs went missing from the Namaka Police Station and the ODPP filed to discontinue proceedings. A Fijian police officer was also charged in relation to the incident, after allegedly scooping up what was believed to be crystal meth powder from the first drug bust. The officer also allegedly fled the scene on Jan. 14 and was apprehended two days later. A Fiji court proceeded to grant bail to the 13 people charged after questioning and holding them in custody for 48 hours per country law. They are still under a curfew and must appear at the Lautoka High Court on Friday.  Fiji Police are now working with their nearby counterparts, like the Australian Federal Police and the Pacific Transnational Crime and Coordination Centre, and expect to make additional arrests. According to Fiji Police Assistant Police Commissioner Mesake Waqa, the drugs arrived in Fiji in late December and the country was “being used as a transit point and that the methamphetamine was destined for a foreign market.” Waqa also said that the exchange of the meth shipment was believed to have been made outside of the country’s Exclusive Economic Zone, and the packages were delivered through a barge. “The Fiji Police Force will not be making further comments on the ongoing investigation until major developments are made,” Waqa said. According to the Fiji Sun, three chiefs — Tui Nadi Ratu Vuniyani Navuniuci, Tui Sabeto Ratu Viliame Mataitoga and Tui Nawaka Ratu Joeli Naevo — have also united to address the issue and naming their concern about drugs in the country. It’s looking as though this incident could ignite a War on Drugs in the region, as entities like the Nadi Chamber of Commerce and Nadi Town Council also urged for swift action to address what they called a “serious and worrying issue.”  Dr. Ram Raju, president of the Nadi Chamber of Commerce and Industry, said that these drug busts were staggering and that Fiji is vulnerable acting as a middle country for illegal drug trade. Raju similarly called for major, sweeping measures, even suggesting that Fiji be deemed as “smoke and drug free.” Pio Tikoduadua, Fijian Parliament minister and member, pointed to the need for legislative review and strengthening the country’s laws around illicit drug trade and border control. Tikoduadua also called for harsher penalties on those involved in the drug trade and building effective processes for police investigations while emphasizing that education is one of the best tools to discourage Fijians from using drugs.

https://hightimes.com/

South Dakota Legislators Shut Down Bill Restricting Medical Cannabis Access for Patients

South Dakota members of the Senate Health and Human Services Committee, with a vote of 5-2, decided last Wednesday to postpone any additional proceedings regarding legislation (SB 82), which aims to limit the medical cannabis access to a sweeping number of patients, NORML reports.  The proposed bill aimed to limit patients to receiving medical cannabis recommendations exclusively from their primary care physician or other healthcare providers suggested by their primary doctor. Any doctors who provided recommendations but did not comply with the bill’s strict criteria would have faced criminal charges. As South Dakota Searchlight reports, out of nine bills proposed to modify South Dakota’s medical cannabis regulations in this legislative session in Pierre, seven are still under review. These include measures to increase the cost of dispensary licenses, authorize cops to search dispensaries, and require prescribers to inform a patient’s primary care doctor when they get their medical cannabis card. According to Jeremiah Murphy, a lobbyist for the Cannabis Industry Association of South Dakota, the good (if you can call it that), news is that of the nine bills, the shut down Senate Bill 82 was the most troubling. It would have made it significantly easier for doctors who offer medical cannabis as a treatment option to face criminal charges. “Senate Bill 82 was absolutely the most critical threat out of what’s out there,” Murphy told South Dakota Searchlight. “They got a lot of feedback from patients on that one. They poked the beehive, and bees came out.”  In his testimony, Murphy stressed that 30% of Americans do not have a primary care physician.  The potential for criminal charges against doctors was a crucial consideration for Sen. Erin Tobin, R-Winner. Tobin, a nurse by profession and chair of the Senate Health and Human Services Committee, also serves on the Medical Marijuana Oversight Committee alongside the bill’s sponsor, Sen. Jim Mehlhaff, R-Pierre. For Tobin, a major issue with the bill was its effort to legally define “primary care provider,” a term and profession that’s tricky to concretely specify due to the flexible nature of roles within our healthcare system. Some folks see specialty doctors for their primary care, others rely on clinics. Putting aside all the War on Drugs rhetoric within the bill, we simply don’t have a solid, organized enough health care system for it to make sense.  Tobin challenged that should the bill pass, doctors who fall somewhere in the gray area, or would as a result, be quite hesitant to prescribe cannabis to patients who would otherwise benefit from it. “If there’s a questionable piece to this, doctors are just going to pull out,” Tobin noted. Back in 2020, South Dakota’s electorate voted to legalize medical cannabis, as favored by 74% of voters. As often happens, in the year since, anti-cannabis lawmakers have put concerted effort into dialing back or revoking this law however possible. There are presently more than 13,000 residents who are officially registered with the state for medical marijuana access, and over 250 practitioners are authorized to provide cannabis recommendations. Opponents additionally pointed to the lack of solid evidence suggesting that anyone is taking advantage of this current system. One must also keep in mind how it would impact the veterans, who often greatly benefit from cannabis for PTSD, who see a primary doctor through the Veterans Affairs Health System. VA doctors currently aren’t allowed to prescribe cannabis. This could be changing.  As High Times reported, in June of 2023, the Senate Appropriations Committee passed a budget bill that incorporates an amendment permitting doctors from the VA to recommend medical cannabis to their patients in states where it’s legal. This amendment is now part of the sanctioned legislation set to finance the VA for the Fiscal Year 2024. The amendment, approved through a voice vote and introduced by Senator Jeff Merkley, an Oregon Democrat, aims for outcomes similar to those in a House-reintroduced bipartisan bill. This bill has the support of Oregon Democrat Representative Earl Blumenauer and Florida Republican Representative Brian Mast, an Army veteran who lost both legs in Afghanistan. Blumenauer and Mast jointly serve as co-chairs of the Congressional Cannabis Caucus. Senator Merkley explained that the recently passed measure in The Senate Appropriations Committee “simply says, in states that have a medical cannabis program, that a veteran’s doctor can talk to their veteran patient about the pros and cons of medical cannabis and fill out related paperwork should a veteran decide to participate in a state program where such paperwork is required.” Back in South Dakota, it’s also important to understand the challenge faced by Native American citizens in finding a primary care doctor. Often, the only viable healthcare option available on these reservations are the physicians at the Indian Health Service (IHS). Similar to the VA, the IHS prohibits its doctors from prescribing medical cannabis, as it remains illegal under federal law. 

https://hightimes.com/

Exclusive: Sen. Kirsten Gillibrand Calls on Biden Administration To Deschedule Cannabis

Sen. Kirsten Gillibrand wants to send the Biden administration a message: End prohibition of cannabis, once and for all, by fully descheduling it rather than simply rescheduling it to a slightly less restrictive category. The time is right for real change. On Sunday, the senator called for Attorney General Merrick Garland and the U.S. Drug Enforcement Administration (DEA) to act to deschedule cannabis at a press conference in Harlem, New York. Cannabis is currently classified as a schedule 1 controlled substance, the most restrictive category and the same as heroin, with “no currently accepted medical use.” “Descheduling marijuana from the Controlled Substances Act is not just a social justice issue; it’s an economic, medical, and public safety issue. Since marijuana was classified as a Schedule I substance during the war on drugs, countless lives have been torn apart, and individuals in primarily Black and brown communities have been targeted for nonviolent cannabis-related offenses,” Gillibrand said. “Studies show that legalizing marijuana could help reduce violence in international drug trafficking and generate billions of dollars for the economy. The vast majority of Americans agree that marijuana should be legalized—that’s why I’m calling on the Attorney General and the Drug Enforcement Administration to swiftly deschedule marijuana from the Controlled Substances Act.” Most recently, the U.S. Department of Health and Human Services (HHS) recommended that the DEA move cannabis to schedule III after careful review by federal authorities, but that may not be enough. High Times asked the senator why it’s critical to deschedule cannabis entirely, versus simply moving it to a less restrictive category. “Rescheduling marijuana will not correct the wrongs of our current judicial system, which has historically targeted Black and brown communities for marijuana related offenses,” Gillibrand told High Times.  The senator continued, “Descheduling marijuana is a critical step toward decriminalization, and it could also reduce violence in international drug trafficking, make the United States competitive in global markets, and generate billions of dollars for the economy.” Gillibrand is joined by Congressman Jerrold Nadler, New York State Senator Cordell Cleare, New York City Council Member Yusef Salaam, New York State Assemblymember Eddie Gibbs, New York State Assemblymember Rev. Al Taylor, Executive Director of Empire State NORML David Holland, and business leaders across New York. Gillibrand also reiterated her stance on social media as the 2024 general election gears up. “Classifying marijuana as a Schedule I drug—something more dangerous than cocaine or fentanyl—has harmed communities and denied critical relief to vulnerable patients,” the senator posted on X. “It’s time to legalize and deschedule marijuana altogether.” The current status of cannabis at the federal level puts individuals at risk, some more than others. The senator has voiced her opinion that cannabis should be legal at the federal level several times before, including the campaign trail of the 2020 general election. In 2017, Gillibrand introduced the Compassionate Access, Research Expansion and Respect (CARERS) Act with Al Franken, Rand Paul, and Cory Booker, and then in 2018, she cosponsored the Marijuana Justice Act along with Sen. Booker. In 2019, when she was running for president of the U.S., Gillibrand released a plan for the national legalization of cannabis, saying that she would make the issue a “top priority” of her presidency. “America’s federal prohibition of marijuana needs to end now,” Gillibrand wrote, acknowledging the need for access to medical cannabis. “Millions of Americans seek medical marijuana to treat chronic or severe pain — often in an effort to avoid prescription opioids — but access is limited by insurance coverage and availability of medical marijuana dispensaries, even in states where medical marijuana is legal,” Gillibrand wrote. “We should be expanding patients’ access to treatment they need, especially when it helps reduce addiction to dangerous medications.” Little action at the federal level isn’t helping anyone, and she believes supporting cannabis could be a major factor in the upcoming general election. Federal authorities have been toying with the idea of rescheduling cannabis to schedule III, and cannabis would be regulated like Tylenol III’s or hormone replacement therapy. If the HHS’ recommendation to reschedule cannabis on the federal Controlled Substances Act becomes a reality, it could make an impact on President Joe Biden’s favorability ahead of the upcoming 2024 presidential election. There is now data to support that idea. A recent survey found broad support across demographics and suggested Biden could see an 11% favorability boost if it occurs. The survey, conducted by Lake Research Partners, revealed a number of key findings surrounding registered voters and attitudes surrounding cannabis, namely that Biden could boost his favorability by 11% among younger voters should cannabis move from Schedule I to Schedule III. “By the end of the poll, impressions of Biden improve by a net double-digits—an 11-point swing overall, including a double-digit (+11-point) swing among younger voters,” the survey notes.  “In conclusion, rescheduling cannabis is not only the right move from a policy perspective, it is also politically helpful,” the survey concludes. “Nowhere is this more true than for younger voters—one of the most cross-pressured groups of voters, and also the most sanguine about rescheduling.” New York leaders like Gillibrand believe reclassifying cannabis under schedule III does not go far enough. Instead, the Biden administration should take a bolder move and deschedule it altogether, giving Americans what they clearly want.

https://hightimes.com/

Long Beach, California To Slash Pot Taxes in Half for Stores in Good Standing

Long Beach, California is on track to establish an ordinance that will give cannabis retailers a minor tax break and reward the ones in good standing on their payments with a bigger tax break, cutting their local tax in half. At a Jan. 23 meeting, Long Beach City Council members voted to request an ordinance be drafted to lower rates for businesses that meet hiring and compensation markers and are up to date with their current tax payments. City leadership has been aware about the significant tax burden impacting cannabis businesses across California. Not only in Long Beach, but California’s entire cannabis supply chain faces a chronic debt problem, and the SF Gate called it an “extinction event” last year. In one move, state law recently shifted the burden of excise taxes from distributors to retailers. Over a dozen cities and counties in the state cut taxes to assist retailers with this dilemma. The tax break fulfills a goal set on April 20, 2023, when the Long Beach City Council vowed to lower tax rates as part of the 2024 annual budget, the Signal-Tribune reported. “We should be aiming to create a positive feedback loop: reduce the tax burden on local operators, allow them to be competitive and expand their businesses, while rewarding those high road employers and operators who make investments back into our community, all while nurturing a new revenue source for the city,” said Councilmember Joni Ricks-Oddie, who brought the item forward. As of the last count available in 2023, Long Beach was home to 32 retail cannabis stores and 37 cultivators. During the Prop. 215 era, the city was home to even more medical cannabis dispensaries. Long Beach Post News reports that Tuesday’s vote advanced a cut at 1 percentage point for retailers with the opportunity to qualify for an additional 3 percentage-point drop if they meet “good standing requirements.” Cannabis cultivators would also get a similar tax break. Their square-footage tax was cut from $14.96 to $13.09, the equivalent of a 1 percentage point cut. A tax break couldn’t come sooner. The city of Long Beach currently imposes a 6% excise tax on medical cannabis transactions and 8% on recreational adult-use cannabis sales, on top of the city’s sales tax of 10.25% and the state’s excise tax of 15%. The state taxes have been imposed since adult-use cannabis use became legal in California in 2016 Long Beach adult-use cannabis sales generated $9 million tax revenue of around $13 million in cannabis tax revenue the city expected to collect in 2023. Several city council members expressed concern over the unpaid taxes, preferring to bring those payments up to date before giving businesses any kind of special tax breaks. “I do think we should have a heavy hand for those businesses that haven’t been compliant with our taxes,” Councilmember Al Austin said at Tuesday’s meeting. “The city needs that revenue.” In order to be eligible for the larger tax breaks, retailers would have to be up to date with licensing and tax payments, and they would have to meet several other requirements. They would also have to ensure that at least 40% of their staff are Long Beach residents and that they are paying their employees between 110% and 115% of the state’s minimum wage. Retailers would also have to support equity businesses by keeping their products on shelves or providing mentoring and incubation support for equity operators. If the changes are fully implemented, the tax cuts are projected to cost the city about $3 million annually.  The 1 percentage point cut for retailers across the board is expected to cost the city just over $1 million, according to data presented to the council. Many local residents complained in recent months that the equity program to support cannabis stores from low-income, justice-impacted residents has resulted in just one successful equity applicant and asked the city to do better.  Others said there’s a great opportunity in the city. Long Beach Green Room owner Adam Hijazi, for instance, said that Long Beach could cut tax rates in order to support legal cannabis businesses and create a cannabis destination in the city.  The city hopes to follow in the footsteps of other California cities like Santa Ana, in providing tax relief by prioritizing businesses that are in good standing, and the ones that give their employees more than minimum wage or provide career opportunities.  Santa Ana took a similar step and implemented a 1% tax cut for most cannabis stores in the city and an additional 2% for “high road” employers.  The council will still have to vote on the ordinance twice before the changes take effect, something that’s expected to happen in the coming months.

https://hightimes.com/

Amsterdam Mayor Advocates for Legal Cocaine Sales

The Mayor of Amsterdam wants to legalize and regulate the sale, possession and use of cocaine.  In an interview with Dutch newspaper Financieele Dagblad, Mayor Femke Halsema very strongly voiced her opinion on drug prohibition and how the decriminalization and legal sale of drugs like cocaine would take power away from organized crime groups who threaten the safety and stability of Amsterdam.  “We have handed the market to unscrupulous criminals. They earn billions. And in the meantime, the war on drugs is disrupting entire countries, causing countless victims and strengthening the criminal business model,” Mayor Halsema said.  Indeed Dutch Customs has recently released a report which supported the notion that organized crime surrounding cocaine trafficking is on the rise in Europe. Dutch Customs seized over 60,000 kilograms of cocaine in 2023 and 51,000 kilograms in 2022. Mayor Halsema has arranged a public debate on the matter which has been scheduled for January 26 in Amsterdam. Cocaine seizures around Europe have followed the same trend with hundreds of metric tonnes seized around the EU year after year. Many reports have attested that the average price of European cocaine has been cut almost in half and the UN reported in March of last year that cocaine production was at an all time high.  “Let us conclude that hundreds of years of discouragement and repression have achieved very little,” Halsema said to Financieele Dagblad. “Apparently people have a need for stimulants. There is a market for that.” Mayor Halsema has been a vocal advocate for change in the City of Amsterdam since her appointment to the role in 2018. She wrote an opinion piece for the Guardian earlier this month in which she expressed that the Netherlands risks becoming a narco-state if steps are not taken to reign in organized crime.  “The widespread use of drugs is integrated into society. The market is enormous. But there are risks to public health and then you should not leave the market to criminals,” Mayor Halsema said to Financieele Dagblad. “Abusing drugs can have serious consequences. But often the risks are exaggerated. Cocaine, for example, is less harmful than alcohol. People make their own choices.” Mayor Halsema also told Bloomberg in July of 2022 that she would be taking steps to cut back on problematic forms of tourism post-COVID. She intimated that Amsterdam needed to pull back from the reputation it has garnered as a sort of safe haven for ne’er do wells who came to her city to take a “vacation from morals.” “In Amsterdam, there’s a state of mind of tolerance. We always argue that cannabis should be legalized and prostitution shouldn’t be criminalized. That is also a part of Amsterdam’s history, a history that we’re very proud of,” Mayor Halsema said to Bloomberg. “But drug culture and prostitution have been internationally commercialized. That is not the way it was intended. We should correct the way we advertised the city in the last 15 years.” This may seem a bit disconnected for a Mayor advocating for legal cocaine sales but from a harm reduction perspective, it makes sense. Mayor Halsema likened it to Amsterdam’s famous red light district which from her perspective is there to provide safety and security to sex workers who, as she puts it, will always be there to serve customers so long as there is a demand for sex work.  The same can be said of cocaine sales. A 2023 report from the European Monitoring Centre for Drugs and Drug Addiction found that cocaine was the second most commonly abused drug in Europe next to cannabis and cocaine seizures in major seaports around the continent have consistently risen every year since 2016. A survey found that almost 2.3 million Europeans between the ages of 15 and 34 had used cocaine in the preceding year. These record increases in use and trafficking led Switzerland to recently open discussions to consider the launch of a pilot program for adult-use recreational cocaine sales in their capital city of Bern. Mayor Halsema appears to have followed suit by doubling down on what she considered to be a common sense approach to drug policy.  “What the Netherlands’ problems reveal is the need for a global shift in the current approach. It’s not a matter of retracting our user-centred policy, but rather advocating for international recognition that the war on drugs is counterproductive,” Mayor Halsema wrote to the Guardian. “The prohibition of drugs is enshrined in international treaties that limit the space for national drug policies, meaning we will have to forge new international alliances that prioritise health and safety over punitive measures.”

https://hightimes.com/

Survey Shows Broad Support for MJ Rescheduling, Boost for Biden if Accomplished

If the Department of Health & Human Services’ (HHS) recommendation to reschedule cannabis on the federal Controlled Substances Act becomes a reality, it could make an impact on President Joe Biden’s favorability ahead of the upcoming 2024 presidential election. A new survey, conducted by Lake Research Partners, revealed a number of key findings surrounding registered voters and attitudes surrounding cannabis, namely that Biden could boost his favorability by 11% among younger voters should cannabis move from Schedule I to Schedule III. To gather the data, researchers engaged 900 likely voters through phone calls and text-to-online outreach. The survey includes oversamples of younger voters and voters in presidential battleground states (100 voters aged 18-25 and 200 voters in battleground states, Arizona, Georgia, Michigan, North Carolina, Nevada, Pennsylvania and Wisconsin). The survey looked more generally at the support behind rescheduling cannabis, with 58% of participants showing support and 19% opposed. Researchers said that support also crossed most demographic lines, and no more than one-third of voters in any major subgroup was opposed to rescheduling. Young voters, those aged 18-25, showed the strongest levels of support for rescheduling at 65%, with nearly half indicating they felt strongly about the issue. Support was strong across age demographics, with seniors showing support by a double-digit margin. Democrats and independents also showed strong support (74% to 7% and 55% to 15%, respectively), while Republicans were more divided (41% to 31%) despite showing more support overall. The survey also found that younger Republicans and Republican women were disproportionately more supportive. Two-thirds (66%) of voters also said that Biden should accept the recommendation, with young voters 18-25 showing overwhelming support (84% with 77% indicating they felt strongly about their answer).  Researchers also found that attacking rescheduling didn’t sway voters, despite the fact that “no punches were pulled” in articulating the opposing viewpoints. These include the rescheduling proposal being a “half measure,” comparing cannabis regulation unfavorably to regulating alcohol, the argument that it will provide “massive profits to pharmaceutical companies” while resulting in “hundreds of thousands of Americans behind bars for marijuana-related offenses). After reviewing opposing arguments for rescheduling cannabis, 58% voters continued to support rescheduling while 18% opposed. Support among young voters remained strong, with 66% behind rescheduling including 50% with strong support. “By the end of the poll, impressions of Biden improve by a net double-digits — an 11-point swing overall, including a double-digit (+11-point) swing among younger voters,” the survey notes.  “In conclusion, rescheduling cannabis is not only the right move from a policy perspective, it is also politically helpful,” the survey concludes. “Nowhere is this more true than for younger voters—one of the most cross-pressured groups of voters, and also the most sanguine about rescheduling.” Concrete talks of rescheduling cannabis first began in Oct. 2022, when Biden made a statement asking the secretary of HHS and the attorney general to review the scheduling of cannabis under federal law. In Aug. 2023, the HHS submitted its recommendation to the DEA to reschedule cannabis from Schedule I to Schedule III.  The U.S. Food and Drug Administration (FDA) also recently said they support reclassifying cannabis as a Schedule III substance, which would make medical cannabis and the research supporting it federally legal but still heavily regulated. The DEA has final authority to schedule, reschedule or deschedule a drug under the DEA and is currently conducting its review. However, there is currently no specific timeframe on when the DEA will make its decision. Researchers also note that the findings of the survey align with a recent Gallup poll, which found that support for legal cannabis hit a record high of 70% among all adults in the U.S. Namely, they highlight that the poll found the highest levels of support in the youngest age cohort, with 78% of the 18-34 age group supporting legalization.

https://hightimes.com/

Delta 9 and Beyond: Your Guide to THC Gummies

Ready to take the plunge and enter the mind-bending world of THC gummies? It’s actually not quite as simple as that. There are different types of THC, each of which is capable of delivering a different kind of THC experience for users. So, with that in mind, we’ve created an easy-to-follow gummy guide for THC users to help you find the chew that best suits your needs.  Before we begin, let’s look at some top products in every cannabinoid category: Best Delta 9 Gummies: CBDfx Magic Melon Delta 9 Gummies, TRĒ House Peach Pear Delta 9 Gummies Best Delta 8 Gummies: TRĒ House Blue Raspberry High-Potency Delta 8 Gummies Best Delta 10 Gummies: TRĒ House Blue Raspberry Delta 10 Gummies Best THC-P Gummies: TRĒ House Tropic Mango THC-P Gummies Best HHC Gummies: TRĒ House Strawberry Burst HHC Gummies Try any of these best-selling gummies and get 25% OFF + FREE ground shipping with code TRYTHC! Let’s start our gummy guide with a quick primer on THC, itself. THC (tetrahydrocannabinol) is one of two major cannabinoids found in the cannabis plant, along with CBD. Cannabinoids are chemical compounds that the plant uses to ward off predatory insects and grazing animals, as well as protect the plant against the elements and attract pollinators.  Your body produces its own cannabinoids, called endocannabinoids, which are part of a cell-signaling system known as the endocannabinoid system. This system helps the body to maintain homeostasis (balance), which affects a variety of functions, including sleep, memory, appetite, motor control, and many more. THC and other cannabinoids interact with sensory receptors in the endocannabinoid system, producing intoxicating or psychoactive effects. That is to say, THC can get you high! While the products we’re looking at today contain THC, they’re not made from marijuana (sorry, no weed gummies). The gummies we’re spotlighting are made with a low-THC form of cannabis, called hemp. Hemp cannabis products (under 0.3% THC) were made legal at the federal level with the passing of the 2018 US Farm Bill. But that doesn’t mean the gummies in question aren’t totally party-ready, as you’ll see shortly. There are several reasons cannabis enthusiasts prefer THC gummies. First, as cannabis edibles, these gummies have longer lasting effects than THC vapes or sublingual oils. In fact, depending on the strength of your THC product and your own personal bioavailability factors (such as height, weight, and THC tolerance), you can enjoy the effects of THC edibles potentially for six to eight hours. And THC-infused gummies taste great, which is an advantage for these canna-chews over capsules. Here’s a handy chart, comparing the effects of edibles versus other types of THC products. Shopping for THC gummies seems pretty straightforward. One could easily assume delta 9 gummies are the only game in town. It’s pure THC, right? But there are several types of THC, which means there are multiple types of cannabis-infused gummies available to consumers.  Delta 9 THC is the big boi. The OG. It’s the cannabinoid one can generally expect to enjoy if a product is simply called, “THC gummies.” In the right quantities, delta 9 can deliver both euphoria, flourishes of creativity, and other uplifting effects—particularly when derived from sativa strains. Indicas lean more on a body high, with blissful relaxation. Either way, you’re in for a good time with D9 gummies. There are several quality brands in the delta 9 THC gummy market. CBDfx, a leader in the CBD industry since 2014, has created a popular line of delta 9 THC products in recent years. Among these products is a potent collection of high-quality delta 9 THC gummies. All of CBDfx’s gummies are made with organic hemp and all-natural ingredients. Each of their products (CBD and THC) is backed by a Certificate of Analysis (COA), which is a third-party lab report that verifies the amount of THC, CBD, and other cannabinoids in your gummies, as well as alerts you to the presence of any pesticides or other toxins. In short, a COA ensures the purity and potency of your product. TRĒ House is the leading brand in recreational hemp products, including THC-infused gummies, syrups, vapes, and prerolls, as well as magic mushroom products. They also use only the highest quality hemp and ingredients, making their delta 9 gummies a must for any stash. TRĒ House’s THC gummy line includes three THC-only gummies, as well as blended gummies with other cannabinoids, including CBD, HHC, and delta 10 THC. TRĒ House offers a wide selection of both delta 8 gummies and delta 10 gummies. Delta 8 and delta 10 THC are isomers of delta 9 THC and have similar effects, albeit in differing intensities. Both have a euphoric buzz that’s similar to delta 9, but a bit more mellow. Of the two, delta 8 is generally considered the more powerful. But the thing to remember is that comparing these cannabinoids mg to mg isn’t always apples to apples when you’re looking at gummy products. A high-potency delta 8 product, like TRĒ House Blue Raspberry Delta 8 Gummies, can have so much D8 content that its effects are comparable to a proper delta 9 product. Like deltas 8 and 10, THC-P is a minor cannabinoid, meaning it only occurs in tiny amounts in cannabis. But THC-P’s effects are massive. It’s estimated that THC-P is 30 times more powerful than delta 9! So, you’ll understand if the milligrams on a THC-P product are comparably low. But rest assured, you’ll get baked as a cobbler. HHC is created by adding hydrogen molecules to delta 9. The result is a gentler THC, making it a great choice for mellow moods. Both make great additions to any stash, particularly if you like a little variety in your seshes. Unsurprisingly, TRĒ House is the place to go for these less common cannabinoids. Their Tropic Mango THC-P Gummies combine THC-P with delta 8 and HHC, giving you a well-balanced head and body vibe. On the HHC side, TRĒ House offers a couple of blended HHC gummies, as well as a potent HHC-only offering. No matter which gummies you choose, always insist on products made with organic hemp and natural ingredients. And make sure to shop with established brands, like CBDfx and TRĒ House, that provide a Certificate of Analysis to ensure you’re getting a pure and potent product every time. It also helps to shop for THC and CBD products from a retailer that understands the importance of carrying quality brands like these, such as CBD.co. At CBD.co, you’ll find a wide range of trusted brands and high-quality products. We hope your THC adventure is a safe and enjoyable one!

https://hightimes.com/

Kansas Advocate Groups Call for Medical Cannabis Legalization

Representatives from the Kansas Cannabis Coalition, Loud Light, and the ACLU of Kansas held an online meeting on Jan. 23 to discuss why they need to call on the Kansas House and Senate to move forward with medical cannabis. Initially, the day was intended to be a “day of action at the Capitol” in Topeka, Kansas, according to the Kansas Reflector, but due to unsafe weather conditions, the meeting was shifted to be held online instead. During the meeting, some people spoke about how they or people they love have found relief in cannabis. Advocate Delaney Jones explained that his grandmother, who survived European concentration camps in World War II, suffered from late detection of pancreatic cancer. She was in intense pain and suffered from the side effects of opioids and chemotherapy, but finally found relief with cannabis oil. “It helped her get rid of the pain and the nausea, even the fatigue at times,” Jones explained. It did not have the side effects of opiate painkillers. We were super, super grateful to see really the magical work that marijuana did in her end-of-life care.” Kansas Cannabis Coalition President Cheryl Kumberg said that five years ago she was assured by legislators that it would take one to two years to put together a medical cannabis bill. I’m here in open-mouth amazement that we are still discussing passing a medical marijuana bill,” said Kumberg. “It is just the same excuses all these years. The same rhetoric from opponents and legislators. We’re just like this little island.” Due to the delay, cities in Kansas have created ordinances to decriminalize cannabis, but statewide legalization is long overdue. “We’ll just have this sort of understanding or unwritten rules and laws that we won’t prosecute cannabis,” said Kansans for Hemp and Kansas Cannabis Coalition member, Kelly Rippel. “It leads to inconsistency around enforcement, not only in communities, but also the district attorneys in counties. We need to have something on the books that says, ‘We are not going to criminalize this, especially for personal possession.’” Rippel added that legislators also need to focus on expunging cannabis-related convictions and record sealing. As an example, Latanya Goodloe, Ladies That Lean executive director based out of Kansas City, Kansas, shared that she served four years in prison for possession and intent to sell. Although she completed her parole in 2009, she ran into challenges for having the felony on her record. Goodloe also believes that the conversation of legalization needs to be accompanied by law that rights the wrongs of the War on Drugs and pursues racial and economic justice. “No monopoly,” Goodloe explained. “Engaging the public, sustainable regulations are key components to shaping a system that addresses both health concerns and economic considerations. At this point, we have no reason to not put marijuana on the table.” ACLU of Kansas legal director Sharon Brett mentioned the parallels between legislator opposition of medical cannabis as well as abortion, citing the similarities of the government attempting to control citizens’ healthcare opportunities. In August 2022, voters rejected a measure that would have amended the Kansas Constitution to state that “the constitution of the state of Kansas does not require government funding of abortion and does not create or secure a right to abortion.” The measure did not pass with 58.97% of voters voting no, and 41.03% voting yes. “Refusal of the Legislature to legalize medical marijuana is the Legislature essentially inserting itself into medical decisions that should be made between a patient and their doctor,” said Brett. “This policy choice is about liberty and autonomy. It is about who is getting to decide important medical decisions—you and your doctors or politicians in Topeka.” Considering that 38 U.S. states, alongside Washington, D.C., and the U.S. territories of the Northern Mariana Islands, Puerto Rico, and Guam, have legalized medical cannabis, advocates feel it is well past time for Kansas to follow suit. In recent history, the Kansas House proposed a medical cannabis bill in March 2021, but it died in committee by May 2021. In March 2023, the Senate Federal and State Affairs Committee shelved a bill that would have legalized medical cannabis, with the chairman saying that they have more important matters to attend to. Gov. Laura Kelly responded to the shelved cannabis bill, calling on the committee to reconsider the bill and take action in the 2023 legislative session. “I am disappointed that some legislators are saying they don’t want to move forward with legalizing medical marijuana this year—effectively turning their backs on our veterans and those with chronic pain and seizure disorders,” Kelly wrote on X in March 2023. “If they get their way, for yet another year thousands of Kansans will be forced to choose between breaking the law and living without pain. I encourage Kansans to call their state legislators and tell them to legalize medical marijuana this session.” To date, no medical cannabis bills have ever made it far enough to land on a governor’s desk in Kansas. Previous Kansas governors, such as Mike Huckabee, weren’t as supportive as Kelly when it comes to cannabis. In October 2022, Huckabee released videos that made claims about adult-use cannabis only benefitting drug cartels and other inaccurate statements. “Unfortunately, you aren’t the one who is going to be making the money, drug cartels will,” Huckabee claimed. “And if you are one of those people that can sell the drug, maybe you’ll make a buck off of the gullible people who will somehow convince themselves this is absolutely harmless.” Poll results published by Fort Hays State University in October 2023 show that two out of every three Kansans support cannabis legalization, with a fairly balanced split between Republicans (75%), Democrats (73%), and Independents (60%). Many participants also said that they would vote for legislators who share support for medical cannabis legalization in particular.

https://hightimes.com/

The Winners of the High Times Cannabis Cup Oregon: People’s Choice Edition 2023

The long-awaited High Times Cannabis Cup Oregon: People’s Choice Edition 2023 results are finally here! It’s been eight months since we announced our return to explore the Beaver State, and the wait has finally ended. It’s an especially unique return too, given that technically we haven’t been back to check out Oregon’s plethora of offerings since our People’s Choice Edition cup was announced in July 2020, and results were published in January 2021. That all being said, a lot has changed since our last in-person cannabis cup event in Oregon, which was held in 2019 (remember the pandemic? It feels like a fever dream now). Back then, we were seeing popular strains Ice Cream Cake, Sundae Driver, Ghost Train Haze, Forbidden Fruit in the winner’s list. Concentrates included a handful of gorgeous diamonds, live resin sauce, sugar, and so much more. (And for edibles lovers, who can forget marshmallow bon-bons, infused lemonade, and fudge.) Then the 2020 Oregon People’s Choice Edition results showed in early 2021. We had to shift some of our planned dates due to devastating wildfires that ravaged the area at the time, but crowd favorite winners were strains such as Strawberry Guava, MAC1, Motorbreath, Blueberry Muffins, and Mimosa that took home awards. Brands like Deschutes Growery, PDX Organics, and Decibel Farms took home multiple awards in categories for flower, while concentrate trends included delicious live rosin and solventless hash rosin. Our edibles category expanded that year, so there were many more crowd favorite chocolates, caramels, gummies, brownies, and cookies. It’s been nearly two years since we’ve asked the good people of Oregon to meticulously rank some of their state’s best products. Now check out the new generation of winners, from returning fan favorites to brand new competitors that seriously impressed our judges. First Place: Culture Farms x Backpack Boyz – Lemon Cherry Roze Second Place: Green Clover Farms – Sour Pistachio Third Place: Eastwood Gardens – Runtz Horchata First Place: Pruf Cultivar – Jack Herer Second Place: Trichome Farms – Black Widow Third Place: Eastwood Gardens – Lemon Royale First Place: Earl Baker – Super Buff Cherry Second Place: Pruf Cultivar – Blue Apricot Sherbet Third Place: Culture Farms – Watermelon Gelato First Place: Trichome Farms – Forbidden Fruit Gelato Pre-roll Second Place: Decibel Farms – Apple Slapz #3 Pre-Roll Third Place: Lit Sticks by PDX Organix – Orange Julius Pre-Roll First Place: Portland Heights – 1G Moonrock Slims Blue Lambo Infused Pre-Roll Second Place: Shadowbox Farms – Douggie Infused Blunt Third Place: Casbah Hash – Hashish Infused Joint First Place: Capital Cannabis – Guava Pie Live Batter Second Place: Dr. Jolly’s x 54 Green Acres – Green Dragon Live Resin Third Place: NW Kind – Lemon Meringue Diamonds & Sauce First Place: Bonsai Farms – Cherry Pie x GG4 Live Rosin Second Place: Cascade Valley Cannabis – Apples & Bananas Live Rosin Third Place: Decibel Dabs – Citrus Palisade #2 Live Rosin First Place: Dr. Jolly’s x Sol Cultivations – Orange Cream Live Resin Vape Second Place: Calyx Crafts – Fat Burger Live Resin Liquid Diamonds All-in-One Vape Third Place: Buddies – Mt Hood Magic Liquid Diamonds Buddies Pod System First Place: Smokiez – Sour Watermelon Fruit Chews Second Place: Electric Lettuce – Summer Edition Cosmic Pop Gummies Third Place: Nelson & Co. Organics – Strawberry Carefree Jellies First Place: Yamba Floss – Blueberry & Strawberry Cotton Candy Second Place: Hapy Kitchen – Toffee Crunch Blondie Third Place: Quality Drugs – Fall Edition Variety Pack Cannabis Infused Caramels First Place: High Desert Pure – Fast-Acting Mango Nano Chill Elixir Second Place: Fruit Lust Flavorz – Strawberry Nano Tech Syrup Third Place: Peak – Rescue Rub 2023 was a huge year for the High Times Cannabis Cup: People’s Choice Edition. In total, we celebrated the results of six competitions in Michigan, SoCal, Illinois, New Mexico, in addition to Oregon, as well as our annual Hemp Cup. That’s just the beginning. 2024 is looking to be a great year as well with our Massachusetts and Arizona People’s Choice Edition competitions well underway. Plus, we have a few more cups announcements soon to come, so keep an eye out for more news in the near future. A special thank you to our partners and sponsors!

FAQ: How to use this hemp news hub

What topics does Chow420’s hemp news cover?

We aggregate and surface reputable coverage on hemp laws and enforcement, THC thresholds and policy proposals, cannabinoid products (CBD/Delta-8/hemp-derived THC), compliance, lab testing, recalls, and broader industry news.

Is this legal advice?

No. This page is for news and education. Hemp rules can change quickly and vary by state—always verify against the latest official guidance and consult qualified counsel for compliance decisions.

How do I evaluate hemp product safety claims?

Look for current third‑party COAs (Certificates of Analysis), clear ingredient labeling, and transparent sourcing. Be cautious with vague potency claims or missing lab reports.

Why do some articles mention Delta‑8 or “hemp-derived THC”?

These products often sit at the center of policy and enforcement changes. We track major updates so shoppers and brands can understand evolving requirements and market impacts.

How often is the news updated?

The crawler is scheduled to run daily. New items appear as sources publish updates.